American Society of Clinical Oncology Choosing Wisely; Last Reviewed 2021 ASCO's 2021 Top Five List in Oncology The American Society of Clinical Oncology (ASCO) is a medical professional oncology ...

All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent criteria across all applications for each ...

All International Development and Education Award (IDEA) applications are carefully reviewed and evaluated by the IDEA Steering Group. The Steering Group scores and ranks the applications using ...

All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent criteria across all applications for each ...

The YIA is a one-year grant totaling $50,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants & Awards Ceremony at the ASCO Annual Meeting. Applicants ...

ASCO’s patient education resources are reviewed by ASCO’s Patient Information Editorial Board, composed of 200+ medical, surgical, radiation, and pediatric oncologists; multidisciplinary members of ...

In addition to gaining a global network of more than 50,000 peers, ASCO membership includes a range of benefits to enhance your career, practice, and research.

The 2025 ASCO Annual Meeting was funded through Conquer Cancer ®, the ASCO Foundation by these generous donors.

The American Society of Clinical Oncology (ASCO) is a medical professional oncology society committed to conquering cancer through research, education, prevention, and delivery of high-quality patient ...

How It Works Through the power of Google Cloud's Vertex AI platform and Gemini models, oncology professionals will have access to timely, trustworthy information drawn solely from ASCO Guidelines. The ...

If you are looking for non-scientific summaries for patients, please visit the Patient Information page. TAPUR Study Analysis Plan The TAPUR Study is a phase II, non-randomized, open-label clinical ...